Nothing Special   »   [go: up one dir, main page]

MX2017013219A - Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos. - Google Patents

Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos.

Info

Publication number
MX2017013219A
MX2017013219A MX2017013219A MX2017013219A MX2017013219A MX 2017013219 A MX2017013219 A MX 2017013219A MX 2017013219 A MX2017013219 A MX 2017013219A MX 2017013219 A MX2017013219 A MX 2017013219A MX 2017013219 A MX2017013219 A MX 2017013219A
Authority
MX
Mexico
Prior art keywords
preparation
methods
crystalline forms
kinase inhibitor
raf kinase
Prior art date
Application number
MX2017013219A
Other languages
English (en)
Inventor
Zhang Guoliang
Zhou Changyou
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of MX2017013219A publication Critical patent/MX2017013219A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42Separation; Purification; Stabilisation; Use of additives
    • C07C51/43Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a sales de maleato de 5-(((1R,1aS, 6bR)-1-(6-(trifluorometil)-1H-benzo[d]imidazol-2-il)-1a,6b-dihidr o-1H-ciclopropa[b]benzofuran-5-iI)oxi)-3,4-dihidro-1,8-naftiridin -2(1H)-ona (Compuesto 1), en particular la sal sesqui-maleato y sus formas cristalinas, métodos de preparación, composiciones farmacéuticas y usos terapéuticos para el tratamiento de enfermedades o trastornos mediados por BRAF u otras quinasas.
MX2017013219A 2015-04-15 2016-04-14 Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos. MX2017013219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015076639 2015-04-15
PCT/CN2016/079251 WO2016165626A1 (en) 2015-04-15 2016-04-14 Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore

Publications (1)

Publication Number Publication Date
MX2017013219A true MX2017013219A (es) 2018-02-15

Family

ID=57125563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013219A MX2017013219A (es) 2015-04-15 2016-04-14 Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos.

Country Status (15)

Country Link
US (1) US10351559B2 (es)
EP (2) EP3283486B1 (es)
JP (3) JP7320741B2 (es)
KR (2) KR102643609B1 (es)
CN (2) CN113307805A (es)
AU (1) AU2016248376B2 (es)
CA (1) CA2981746C (es)
EA (1) EA035680B1 (es)
IL (2) IL255555B (es)
MX (1) MX2017013219A (es)
NZ (1) NZ735715A (es)
SG (1) SG11201707984TA (es)
TW (3) TWI736531B (es)
WO (1) WO2016165626A1 (es)
ZA (1) ZA201706392B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
MX352617B (es) 2011-12-31 2017-12-01 Beigene Ltd Compuestos triciclicos fusionados como inhibidores de cinasa raf.
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
TWI736531B (zh) 2015-04-15 2021-08-21 英屬開曼群島商百濟神州有限公司 B-raf 激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途
JP6993056B2 (ja) 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのpd-1アンタゴニスト及びraf阻害剤の組合せ
KR20240032157A (ko) 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
JP2021533154A (ja) * 2018-08-06 2021-12-02 アルデイラ セラピューティクス, インコーポレイテッド 多形化合物およびその使用
LT3873894T (lt) * 2018-10-31 2023-06-26 Les Laboratoires Servier Naujoji bcl-2 inhibitoriaus druska, susijusi kristalinė forma, jos gamybos būdas ir farmacinės kompozicijos, kurių sudėtyje ji yra
CN111484489B (zh) * 2019-01-25 2023-05-23 百济神州(北京)生物科技有限公司 无定形的b-raf激酶二聚体抑制剂
CN111484488A (zh) * 2019-01-25 2020-08-04 百济神州(北京)生物科技有限公司 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス, インコーポレイテッド 多形化合物およびその使用
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2023240178A1 (en) * 2022-06-08 2023-12-14 Mapkure, Llc Methods of treating cancer with a b-raf inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828186A1 (en) 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
WO2007067444A1 (en) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
US7442808B2 (en) 2006-05-15 2008-10-28 Merck & Co., Inc. Antidiabetic bicyclic compounds
ES2373587T3 (es) 2006-08-23 2012-02-06 Pfizer Products Inc. Compuestos de pirimidona como inhibidores de gsk-3.
WO2008030448A1 (en) 2006-09-07 2008-03-13 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
KR20090130345A (ko) 2007-05-04 2009-12-22 아이알엠 엘엘씨 C-kit 및 pdgfr 키나제 억제제로서의 화합물 및 조성물
US20100197924A1 (en) * 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
WO2012121764A1 (en) * 2010-11-25 2012-09-13 Ratiopharm Gmbh Novel salts and polymorphic forms of afatinib
MX352617B (es) * 2011-12-31 2017-12-01 Beigene Ltd Compuestos triciclicos fusionados como inhibidores de cinasa raf.
TWI736531B (zh) 2015-04-15 2021-08-21 英屬開曼群島商百濟神州有限公司 B-raf 激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途

Also Published As

Publication number Publication date
TWI792406B (zh) 2023-02-11
TWI832668B (zh) 2024-02-11
JP2024012540A (ja) 2024-01-30
BR112017020945A2 (pt) 2018-07-10
KR102643609B1 (ko) 2024-03-05
WO2016165626A1 (en) 2016-10-20
TW202330526A (zh) 2023-08-01
KR20170139073A (ko) 2017-12-18
EP3283486A4 (en) 2018-08-22
CN107531682A (zh) 2018-01-02
TW201702241A (zh) 2017-01-16
AU2016248376B2 (en) 2020-10-08
IL287740A (en) 2021-12-01
CA2981746A1 (en) 2016-10-20
EP3283486B1 (en) 2022-07-27
EA201792254A1 (ru) 2018-02-28
US20180127412A1 (en) 2018-05-10
EP4119559A1 (en) 2023-01-18
JP2018511634A (ja) 2018-04-26
EA035680B1 (ru) 2020-07-24
EP3283486A1 (en) 2018-02-21
ZA201706392B (en) 2019-05-29
JP7320741B2 (ja) 2023-08-04
SG11201707984TA (en) 2017-11-29
US10351559B2 (en) 2019-07-16
TWI736531B (zh) 2021-08-21
IL255555A (en) 2018-01-31
CA2981746C (en) 2023-08-01
AU2016248376A1 (en) 2017-10-12
KR20240049684A (ko) 2024-04-16
CN113307805A (zh) 2021-08-27
NZ735715A (en) 2022-09-30
JP7383652B2 (ja) 2023-11-20
IL255555B (en) 2021-12-01
TW202138370A (zh) 2021-10-16
CN107531682B (zh) 2021-05-04
JP2021073246A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
MX2017013219A (es) Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos.
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2016009403A (es) Compuestos heterociclicos.
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
SA518400333B1 (ar) شكل متعدد الأشكال من n- {6-(2-هيدروكسي بروبان-2-يل) -2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
MX2016009581A (es) Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
PH12016502432A1 (en) 1h-1,8-naphthyridin-2-ones as anti proliferative compounds
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
NZ712369A (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
EA202190043A2 (ru) Замещенные гетероциклические производные как ингибиторы циклин-зависимой киназы (cdk)